MDR TB Rapid Genotypic

The MDR-TB Rapid Genotypic Test detects mutations in the Mycobacterium tuberculosis genome that confer resistance to rifampicin and isoniazid, the two most critical first-line anti-TB drugs. It identifies multidrug-resistant TB (MDR-TB) quickly, enabling timely treatment modifications.

This test is recommended for:

• Patients diagnosed with TB who are not responding to standard treatment.
• Individuals with a history of previous TB treatment or relapse.
• Contacts of known MDR-TB patients.

The test is performed on a sputum sample or other appropriate clinical specimens using molecular techniques such as PCR (polymerase chain reaction) to detect drug resistance mutations.

• Positive for MDR-TB: Indicates resistance to rifampicin and/or isoniazid, requiring second-line treatment.
• Negative for MDR-TB: Suggests susceptibility to first-line drugs, though additional tests may be required for confirmation.

By detecting resistance early, the test allows for appropriate treatment adjustments, preventing the spread of drug-resistant TB and improving patient outcomes.